Virus isolation and serum neutralizing antibody titers were determined over a period of time from samples collected from animals persistently infected with bovine viral diarrhea virus (BVDV). To evaluate over time the ability to detect BVDV by virus isolation from serum or white blood cell preparations, 4 persistently infected calves were monitored from birth until 70 days of age. In 3 of 4 persistently infected calves, virus isolation from serum and white blood cells was negative until approximately 42 days of age, when colostral antibody had declined. The level of viremia in 7 adult (Ͼ12 months) persistently infected animals decreased by 1 10-fold dilution over at least a 2-year period. The level of viremia became undetectable by virus isolation from serum in 1 of the 7 animals examined. This decline was associated with the development of virus neutralizing antibody. Although the level of viremia is fairly stable within persistently infected animals, the presence of specific neutralizing antibody may affect the ability to isolate BVDV. These findings are important when considering diagnostic testing to identify persistently infected animals by virus isolation.
An important aspect of the biology and pathogenesis of bovine viral diarrhea virus (BVDV) is persistent infection that occurs following in utero infection of the bovine fetus. The development of persistently infected animals contributes significantly to the high prevalence of BVDV infections. Because persistently infected animals are a continuous source of virus, the identification and removal of persistently infected animals is an essential component of current prevention and control measures.
The identification of persistently infected animals is routinely done by virus isolation from white blood cells or serum. To detect noncytopathic BVDV, an immunoperoxidase microtiter plate assay is commonly used. 1 The presence of low levels of virus or the presence of anti-BVDV antibody may interfere with the ability to isolate BVDV in cell culture from blood samples. 9 Although levels of viremia in persistently infected animals have been characterized, 7 little information is available on the variability or stability of the viremia in persistently infected animals over time. Therefore, the purpose of this study was to characterize levels of viremia present in 7 persistently infected cattle over a period of 4 years. In addition, 4 persistently infected calves were monitored from birth until 70 days of age.
Materials and methods
Animals. Seven persistently infected cattle obtained from different privately owned herds were evaluated at various intervals during a 4-yr period. Four of these animals (SD-1, LR91, Charolais, Marvin) were kept in individual isolation rooms in an isolation facility; the other 3 were kept in individual pens in an isolated barn during the sampling period. Four additional persistently infected calves were monitored from the day of birth until 70 days of age. The dams of these 4 calves were experimentally inoculated with SD-1 BVDV from 40 to 100 days of gestation. Within 12 hr following birth, blood samples were collected and all calves were given, via esophageal tube feeder, 2 liters of colostrum collected from their respective dams.
Samples. Serum was obtained from clotted blood samples collected at various intervals during the sampling period from the persistently infected heifers. Serum and whole blood samples (collected in ethylenediaminetetraacetic acid) were collected from persistently infected calves within 12 hr following birth and at weekly intervals until 70 days of age. Samples were stored at Ϫ80 C.
Laboratory testing. Serum virus neutralization was performed in microtiter plates as previously described. 9 Neutralization titers were determined using 3 different BVDV reference strains; cytopathic NADL, noncytopathic SD-1, and noncytopathic BJ virus.
Levels of serum viremia were determined by making serial 10-fold dilutions of serum in triplicate. Dilutions of each sample were made in Dulbecco's modified Eagle medium (DMEM), and 250 l was placed in microtiter wells containing bovine turbinate (BTU) cells and incubated for 1 hr. Virus isolation from white blood cells (WBC) was performed by removing the buffy coat layer from 10 ml of whole blood following centrifugation. The red blood cells in the buffy coat fraction were lysed by the addition of 10.0 ml of 0.15 M NH 4 Cl, and the solution was centrifuged. The WBC pellet was washed with 10.0 ml of DMEM and recen- 1 1 0 6.5 * 1 0 1.0 * 1 0 7.0 * 1 0 6.5 * 1 0 6.5 * 1 0 6.0 * 1 0 6.0 * 1 0 6.3 * 1 0 trifuged. The WBC were suspended in 0.5 ml of DMEM and frozen at Ϫ80 C. After thawing, 50 l of the suspension was added to the well and incubated for 1 hr. Following incubation, the virus inoculum was removed and replaced with fresh medium. Virus isolation was detected by immunoperoxidase staining of BTU cell monolayers following 3 days of incubation or, for the cytopathic NADL, by cytopathic effect. 1 Virus isolation was confirmed by 1 additional serial passage in a microtiter plate.
Virus characterization. BJ-91 virus (isolated from serum on September 24, 1991) and BJ-93 virus (isolated from WBC on September 30, 1993) were compared at the antigenic level by monoclonal antibody (MAb) binding. The 29 MAbs used possessed viral neutralizing activity and reacted with the BVDV E2 polypeptide (gp53). Monoclonal antibodies were prepared and characterized as described previously, 4 and MAb binding was assessed by indirect immunoperoxidase staining of infected cell monolayers. 3 Genomic typing was determined using polymerase chain reaction (PCR)-based tests based on the 5Ј untranslated region (UTR) and the genomic region coding for the NS2-3 BVDV polypeptide (p125). 13 To generate viral template, total RNA from BVDV-infected BTU cells was prepared by acid guanidinium thiocyanate/phenol/chloroform extraction as adapted for cell culture. 8, 10 This procedure was modified by using 5/1 phenol/chloroform (pH 4.7) instead of water-saturated phenol. Total RNA was harvested from BTU cells 48 hr after infection with BVDV. Reverse transcription and PCR amplification were performed as described previously. 13 
Results
Samples collected within 12 hours following the birth of the 4 calves indicated the presence of BVDV (Table 1 ). Only 1 (calf 1) of the 4 calves sampled maintained a detectable viremia following the intake of colostrum. In addition, the serum level of passively transferred anti-BVDV antibody was reduced in calf 1 compared with the other 3 calves ( Table 2 ). Testing of colostrum given to calves 1, 2, 3 and 4 indicated that BVDV antibody was present at levels of 1:2,560, 1: 2,560, Ͼ1:5,120 and Ͼ1:5,120, respectively. At approximately 56 days of age, viremia became detectable in the serum of the 3 remaining calves (Table 1) . Virus was isolated from WBC collected from all 4 calves by 42 days of age. The ability to detect the viremia correlated with a precipitous drop in the level of anti-BVDV neutralizing antibody ( Table 2 ). All 4 calves were determined to be persistently infected by repeated positive virus isolation from serum and WBC samples and PCR amplification beyond the 70-day sampling period.
In 5 of the 7 mature, persistently infected animals, the average serum BVDV titers as determined by virus isolation declined (during the period available) from 2.2 ϫ 10 5 to 1.1 ϫ 10 4 CCID 50 /ml of serum (Table 3 ). In most of the mature, persistently infected animals, a decline was detected only after a period of approximately 2 years. One persistently infected animal (Charolais) had a 10-fold increase in the level of viremia over a 2-year period ( Table 3 ). Six of the mature, persistently infected animals did not have or develop virus neutralizing antibody titers against BVDV as determined with 3 reference strains of type I BVDV in a viral neutralization assay (NADL, SD-1, BJ). Virus neutralizing antibody was detected in 1 persistently infected animal (BJ). SD-1 5 ϫ 10 5 (1/89) 5 ϫ 10 3 5.5 BJ 5 ϫ 10 3 (9/91) 0* 3 RLH 5 ϫ 10 4 (7/90) 5 ϫ 10 2 3.5 Marvin 5 ϫ 10 3 (10/89) 5 ϫ 10 2 4.5 9120 5 ϫ 10 4 (6/91) 5 ϫ 10 2 3 Charolais 1 ϫ 10 4 (9/91) 1 ϫ 10 5 3 007 5 ϫ 10 5 (9/91) 5 ϫ 10 4 2.5 * Positive titer from white blood cell samples. 
During the sampling period, the level of viremia present in BJ was initially 5 ϫ 10 3 CCID 50 /ml of serum. Subsequently, the viremia dropped to a level that could not be detected by virus isolation following 3 passages in cell culture (Table 4 ). During this period when virus was not isolated from serum, BVDV was isolated at low concentrations from WBC preparations. Subsequently, BVDV reappeared in serum at a low concentration of 10 1.3 CCID 50 /ml of serum. In addition, coincident with the changes in serum virus levels was the development of neutralizing antibody against BVDV. During this period, the virus neutralizing antibody titer was 1:5 against SD-1 BVDV but rose to 1:160 against the homologous BVDV BJ, which persistently infected the BJ heifer (Table 4 ).
Viral stocks were prepared from the initial BJ isolate September 1991 (isolated from serum) and from an isolate obtained September 1993 (isolated from WBC), identified as BJ-91 and BJ-93, respectively. Further characterization of these isolates using monoclonal antibody binding and nucleic acid sequence comparison indicated that the viruses were identical. Both viruses were identified as type 1 according to 5ЈUTR and NS2 PCR analysis. The BJ-91 and BJ-93 isolates had identical MAb binding patterns (Table 5 ) and had 100% nucleotide sequence homology within the 5ЈUTR region extending from nucleotide 100 to nucleotide 360. Analysis of the anti-BVDV antibody in serum collected from BJ by radioimmunoprecipitation indicated antigen-specific reactivity to the E2 protein of the BJ-91 virus isolate (data not shown).
Discussion
Passively acquired colostral antibody caused a precipitous drop in the virus concentration in serum of neonatal, persistently infected calves. The decrease in the concentration of virus in serum was correlated with detection and persistence of colostral antibody in serum from the calves. This decrease in serum viremia is important when considering the sampling of young calves for BVDV isolation. The viremia present in per-sistently infected calves has been characterized previously by monitoring 11 persistently infected calves for 20 weeks following birth. In all 11 calves, the presence of antibody titers as low as 1:16-1:24 prevented virus detection in blood samples by virus isolation. 11 Virus was detected in all 11 calves at 6-8 weeks of age following the disappearance of colostrol antibody. 11 One explanation for the inability to detect BVDV from WBC by virus isolation may be the manner in which the WBC fraction was processed prior to virus isolation. In this study, all WBC samples underwent 1 freeze/thaw cycle prior to cell culture inoculation. This process may have released free virus, which was neutralized by passive antibody. Further comparative studies are needed to determine if processing methods allowing the coculture of fresh intact WBC provide a more sensitive method of virus isolation when moderate to high level of passively acquired colostral antibody are present.
It is generally accepted that when conducting herd screening for BVDV using serum, calves Ͻ3 months of age should not be included. In this study, virus isolation from WBC was negative in calves until 42 days of age (Tables 1, 2) . Although samples can be collected from animals Ͻ3 months of age, WBC and serum may be negative by virus isolation. In calves Ͻ3 months of age, alternative methods of detection, such as PCR amplification, may provide a better level of sensitivity. 5, 6 Detection of virus by PCR is not affected by the presence of antibody.
The prevention and control of BVDV is dependent on the identification and removal of persistently infected animals from the herd and on an effective vaccination program. A common method for the identification of persistently infected animals is virus isolation from serum. Although the serum concentration of BVDV declined gradually in all persistently infected animals over at least a 2-year period, the concentrations of virus remained sufficient to allow virus isolation by standard methods. Viral concentrations in serum can vary among persistently infected animals. Concentrations of 10 4 -10 6 CCID 50 /ml of serum have been reported. 7, 11, 12 The virus concentrations detected in the persistently infected animals in this study were typical for persistently infected cattle. In 6 of 7 animals, a gradual decline in serum virus concentration was not associated with the development of detectable neutralizing antibody titers against the 3 reference strains of BVDV used in the virus neutralization assay. The precipitous drop in serum virus concentration that occurred in the persistently infected animal BJ may have major implications for control and prevention strategies involving herd screening using serum samples.
It is generally accepted that persistently infected animals have detectable concentrations of virus in serum following the decline of passively acquired antibody. In addition, the development of neutralizing antibody in persistently infected animals has been described following vaccination with a modified-live BVDV vaccine. 2 However, an absence of detectable concentration of virus in serum and the spontaneous production of virus neutralizing antibody by persistently infected cat-tle has not been described. This is the first reported case of the disappearance of virus from serum in a persistently infected animal due to the spontaneous production of virus neutralizing antibody. This finding has important implications for the use of serum for virus isolation to identify persistently infected animals. If persistently infected animals develop neutralizing antibody, virus isolation may only be possible from WBC preparations. In the persistently infected animal BJ, isolation of BVDV from WBC was possible despite the presence of virus neutralizing antibody in serum. Collecting an adequate volume of whole blood (10 ml) and the subsequent processing to obtain white blood cells become important factors in the ability to isolate BVDV in the presence of neutralizing antibody.
To determine a possible explanation for the complete abolition of virus from serum, the initial virus isolate obtained from serum (BJ-91) was compared with an isolate obtained from the WBC fraction following the abolition of a detectable concentration of virus in serum (BJ-93). Both isolates were characterized as a type I virus by PCR analysis of the NS2 region and the 5ЈUTR and by MAb panel reactivity (Table 2 ). Most likely, the 2 virus isolates are indistinguishable because of an identical pattern of MAb reactivity with 29 neutralizing MAb to the E2 protein (Table 2) and the complete (100%) homology of the aligned 5ЈUTR nucleotide sequence. The identical antigenic characteristics of the 2 sequential viral isolates as determined by MAb binding may indicate that the initial persistent virus did not undergo antigenic drift, which would allow it to escape the antibody response. The stimulus for the antibody response is puzzling. One explanation is that the persistently infected animal was exposed to a different antigenic strain of field virus and developed cross-reactive antibody that removed cell-free virus from serum. Previously, antibodies have been identified in a persistently infected animal that immunoprecipitated the E2 protein of BVDV before and following vaccination with a modified-live vaccine. 2 Another possible explanation may be the deterioration of immunotolerance to the persistent BVDV and subsequent stimulation of antibody.
The changes in the concentration of virus in serum obtained from the persistently infected animal BJ have important implications. As more effective vaccines are developed with a broader representation of BVDV antigens, what will be the ramifications of the vaccination of persistently infected animals? The absence of cell-free virus in serum from a persistently infected animal demonstrates that our understanding of BVDV and its pathogenesis is not complete. The techniques for diagnostic identification of BVDV in field samples and for the formulation of prevention and control strategies in infected herds must be continually assessed and evaluated. Control strategies must include the identification and removal of persistently infected animals and implementation of proper vaccination programs.
